Carole Ho compensation by year
Denali Therapeutics Summary Compensation Table · all 9 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $406,850 | $423,124 | $440,000 | $457,600 | $473,616 | $500,000 | $520,000 | $535,600 | $483,000 |
| Bonus | $203,425 | $371,187 | $176,000 | $366,080 | $284,170 | $225,000 | $269,093 | $337,416 | $0 |
| Stock awards | $0 | $179,673 | $305,830 | $1,382,774 | $2,125,800 | $2,307,095 | $1,136,146 | $1,092,128 | $1,151,867 |
| Option awards | $746,025 | $2,948,616 | $1,558,941 | $2,107,493 | $3,648,420 | $2,647,757 | $2,230,744 | $2,043,815 | $2,180,003 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $11,697 | $12,869 | $8,800 | $11,400 | $11,600 | $12,200 | $13,200 | $13,800 | $14,000 |
| Total | $1,367,997 | $3,935,469 | $2,489,571 | $4,325,347 | $6,543,606 | $5,692,052 | $4,169,183 | $4,022,759 | $3,828,870 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Denali Therapeutics Inc. DEF 14A filed April 21, 2026, accession 0001714899-26-000054, and prior-year filings.
How this page was built: the Denali Therapeutics Inc. filed document, accession 0001714899-26-000054. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 54,180 | $894,512 | — |
| RSU | 40,290 | $665,188 | — |
| RSU | 20,560 | $339,446 | — |
| RSU | 7,750 | $127,953 | — |
| RSU | 5,625 | $92,869 | — |
| Option | 162,540 | — | $21.26 |
| Option | 83,938 | — | $20.33 |
| Option | 33,411 | — | $27.63 |
| Option | 1,939 | — | $47.27 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Denali Therapeutics Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Denali Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Ryan Watts | President and Chief Executive Officer | $4,751,515 |
| Alexander Schuth | Chief Operating and Financial Officer and Secretary | $4,258,045 |
| Carole Ho · this page | Chief Medical Officer and Head of Development (until November 14, 2025) | $3,828,870 |
Carole Ho's compensation dossier, Denali Therapeutics
You have read Carole Ho's totals and holdings. The dossier adds each equity grant Denali Therapeutics disclosed for Carole Ho and Denali Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Denali Therapeutics compensation record
free company briefThis page is one person within Denali Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Denali Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Denali Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Denali Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.